Abstract

Tissue Metabonomic Study of Giant Cell Tumor of Bone

Francisco Javier Martínez-López, Student, Instituto Politecnico Nacional

The giant cell tumor (GCT) comprises 5% of primary bone tumors and 20% of benign tumors of the skeleton. It usually develops in the third decade of life affecting the epiphysis of long bones. Classically, patients with GCT manifest pain associated with physical activity and pathological fractures especially in load-bearing bones. 1. Although GCT shows histologically benign appearance has an unpredictable clinical course. The GCT recurs in 20-40% of cases subsequently to the intra-lesional or marginal excision. Moreover, the development of pulmonary metastases is reported in 1-6% of cases by hematogenous spread of the lesion. 2. The standard treatment is substantial surgical resection; in parallel other treatments are continuously being explored, as the monoclonal antibody Denosumab. 3. However, several molecular pathogenesis aspects of GCT still require further understanding for the development of targeted treatments or early diagnosis. In this study, the tissue metabolomics profiling was approached by untargeted 1H nuclear magnetic resonance of GCT and profiled to determine the significant alterations. The metabonomic results demonstrate clear inter-group differences between control and TCG tissue in the partial least-squares-discriminant analysis (PLS-DA) model. Differential metabolites identified suggest an alterated metabolism in TCG, as characterized by significantly upregulated methionine metabolism and phospholipid biosynthesis.